CEOInterviews.AI
Start App
Get an email when Robert Langer gives a new interview
One email per new interview. Unsubscribe in one click.
Robert Langer
Institute Professor, MIT

Bob Langer MIT HEALS Fireside Chat 2026 05 06 Broad Institute

📅 May 06, 2026 Jack Kwan 52 MIN 30 VIEWS 77 SEGMENTS · 3 SPEAKERS

Questions asked in this interview

12
  1. 2:34How about humanities and social sciences?
  2. 5:02I want to know, you know, what motivated you to actually build that bridge, and how did you make the leap from chemical engineering to biotech and biomedicine?
  3. 10:23How do you actually decide which is going to be the biology match for some engineering innovation?
  4. 12:13Do you do, maybe there's never any doubt anymore about what Bob Langer can do, but what did you do to start to kind of keep going and persevere toward your goals when, you know, there are just a lot of doubters out there?
  5. 13:51This is something we don't have classes in, right?
  6. 18:43... work, and how, how can you, what can the school do to push more people to be this successful, but at the same time, what can, what would you have wished MIT to do more, or what makes MIT special and allowed you to do what you did?
  7. 31:42So my question is, when do you think is the right time for a technology to spin out versus how long should you kind of keep de-risking and incubating something at MIT?
  8. 34:36How did you find time to do all this stuff over your career?
  9. 38:32But since you — if you want to expand on that, but also I'll tag on another question: what do you see AI and machine learning — how do you see this changing the research in your lab today and in the future?
  10. 44:14And you know, as investigators, as discoverers, as scientists, you know, we're taught to spread it as far and wide as fast as possible, right?
  11. 45:04You know, just I think that for this audience, where we see both of these realms side by side all the time, you know, what are the conflicts and what are the pathways to resolve them?
  12. 49:11... are your thoughts on what are the key points in drug delivery that still need to be addressed in the context of vaccines that target mucosal immunity versus in order for them to be as impactful as the ones that target the general immunity?
Susan Hockfield 0:07 ↗
This is the second event in a new seminar series we call the Innovation Frontier: Insider Stories, and the series is part of MIT Heals, which is the Institute of Health and Life Sciences collaborative. In these sessions, we are focusing on how lab discoveries in the life sciences translate into world and life-changing products. And I think, and it's hard to be at MIT and not be aware of just, you know, while I'm off campus, you know, into companies. It's, I don't know, it's entirely unique, but it sure is a different kind of ethos from any other place I've been or any place I've visited. So, just to introduce who we are in the series. So many of you know I'm Susan Hockfield. I'm the Whitehead Professor of Neuroscience and I'm a member, a proud member of MIT's Koch Institute for Integrative Cancer Research.
I served as MIT's president from 2004 to 2012, and that was a really vibrant area. We had a rapid acceleration of the convergence of biology, engineering, and medicine. And we are, you know, full-thrown in the midst of that convergence, which is driving many of the technologies that we'll be showcasing in the series. So our speakers in the series are company founders, and they bring their insights to us in the early stages of biotech companies. It's a delight to introduce someone today who doesn't really need any introduction. It's our great good fortune to have MIT Institute Professor Robert Langer, otherwise known as Bob. So many of you might not know, but the Institute Professorship is our highest honor for our professors, and there are only nine of them, and it is really impossible for me to fully describe or even partially describe Bob's accomplishments, so I'm going to mention only a few that, you know, really kind of, you know, called out to me as signature components of Bob's history. So he, like all faculty, writes papers with his students and postdocs and colleagues, and those papers have been cited over 475,000 times.
Some of us are laggards in that domain. And his h-index of 337 is the highest of any engineer in history. But importantly, Bob doesn't just write brilliant papers. He puts his discoveries into practice. His patents have been licensed or sublicensed to over 400 companies. We're talking impact here. He's founded, co-founded more than 40 ventures, including Moderna, and he holds 45 honorary doctorates and has received 220 awards, including both the United States National Medal of Science and the US National Medal of Technology and Innovation. He's only one of three, he's one of only three living individuals to have received both of those honors. And I would say that is just a little sliver from this huge list of spectacular accomplishments. So this is a little different from most seminars. Our goal in the series is to engage you in the conversation. Bob and I are going to kick off today's session with a very brief introduction, simply to get things going and introduce Bob to those of you who don't know him as well as I do. But as most of you know, he's a legendary engineer and entrepreneur. Bob and I are going to start things off with a short conversation, about 15 minutes, and then we're going to devote the rest of our time to your questions. So please, please, please, I encourage you, I exhort you to join our conversation with your curiosity. We want your questions to drive the conversation, and it'll also drive the insights we're going to gain from today's conversation. So before we start, let's get an idea of who we have in our audience. So how many of you could raise your hands are students? Any undergraduates? How about graduate students and postgrads? Postdocs. Great. Terrific. And who among you are in a STEM discipline? Almost everyone. Popular or world of biology. Yes. Anyone here from business? Anyone here from the Sloan School? Great. How about humanities and social sciences? Terrific. Anyway, thank you all for joining us. Okay, we're going to get started, Bob.
Robert Langer 5:01 ↗
Sounds good.
Susan Hockfield 5:02 ↗
Yeah, excited to do this. So thank you for joining me. It's always fun to talk with you. It's always a privilege. And we're going to begin with your earliest insight that you could bridge engineering and medicine. Now, you know, we kind of take that for granted today, but you were a very early adopter of that thesis that biology and, sorry, engineering and medicine could have things to talk to one another about, and that it could really change the face of what medicine had been. And so, was there a particular problem or a particular challenge that couldn't be addressed by one or the other alone? I want to know, you know, what motivated you to actually build that bridge, and how did you make the leap from chemical engineering to biotech and biomedicine?
Robert Langer 6:02 ↗
Yeah. Well, it's a great question. Let me, let me try to say a few things. I, I think they're, they're almost different things. How I got involved in medicine, I, I'd like to tell you that I had it really well thought out, which wouldn't be true. I, I really, when I got done with my degree actually from here in 1974, you know, almost every chemical engineer went to work for an oil company, and I really wasn't that excited about it when I, I went for these interviews, and I, I kept looking for something that I could do to help people. I thought about teaching, and I got very involved in helping start a local school for low-income kids, and I tried to get a job doing, developing chemistry curriculum, and that's what I was doing, math curriculum, and I couldn't get any place to hire me. And then, so then I did think about medicine as a way I might, maybe I, but I didn't necessarily know what I'd be doing. But, but that, so I went to work at Children's Hospital with a man named Judah Folkman, and I, I was the only engineer there.
But that being said, to the point you're making, I think a great number of ways that I got to see how engineering could make a difference in medicine, and how that thinking might help. And let me maybe just give one example, which I didn't realize right away, but when I was over at the hospital, I was working on materials. So I was curious, how did materials find their way into medicine? And almost everything that was done up until this time was basically a medical doctor going to their house and trying to pick a material in their house that kind of resembled the organ or tissue they wanted to fix. So, for example, the artificial heart, which was developed, initial ones in 1967, they picked a lady's girdle because it had a good flex line. And then, like for, you know, for breast implant, they picked a mattress. You know, the first one was, you know, polyurethane, the other was a foam. And those, you know, made progress, but they also caused problems. Blood is the surface of the artificial heart, and it could form a clot and go to the patient's brain and get a stroke, and they die. So I started thinking, you know, what you learn in chemical engineering was like design. You could ask the question, what do you really want in the material, biomaterial, from an engineering standpoint, chemistry standpoint, biology standpoint, and then try to synthesize it. So we kept doing a lot of things like that, but there are lots of examples like that.
Susan Hockfield 8:44 ↗
So how did you actually, tell us about how you actually made the match with medicine. So what was your first...
Robert Langer 8:52 ↗
Yeah. Well, the... Well, so the big project that I worked on too, Judah Folkman had this idea that if you could stop blood vessels from growing, that might be a way to stop cancer. And so, and he had had a lot of, I think, pretty, you know, biochemists and other people work on that, but it wasn't really happening. So when he asked me to join, you know, one of the things that we wanted to develop better was what we call a bioassay, blood vessel growth. Problem with studying it is there's always a lot of background blood vessels wherever you go. But there are a couple of places where there are none or very few. The chick chorioallantoic membrane is one, and the cornea is another. So we had this assay we were trying to do where we put a tumor in some of these sites. But then we needed a tiny little nano or microparticle that we could put right next to it to deliver some of the different things isolated, all of which were very large molecules, and that hadn't been done before, and people actually didn't think that was possible. He was on the advisory board of Alza, which was the only company in the country at that time working on advanced drug delivery systems. So that was how I got involved, was trying to develop these little nano and microparticles that could deliver these large molecules, and then using that to see if we could isolate for the first time these blood vessel inhibition.
Susan Hockfield 10:23 ↗
Fantastic. So, you know, in biology, fundamental biology, there are, you know, new discoveries every day. I particularly now, I mean, I'm reflecting a lot on the accelerated pace of advances in biological sciences, and, you know, and this is true in biotech. And so how do you decide which ones are worth pursuing? How do you actually decide which is going to be the biology match for some engineering innovation?
Robert Langer 10:50 ↗
Yeah. Well, if it's for... Yeah. Well, I think if, part of it is if you're looking at academics, that's one thing. I think they're, you know, you could have a long timeline, and I think that I probably judge it on impact, I think, or perceived impact. I think if you're doing it at a company, you really have to have made something. You're going to get, you know, the road in medicine is long, you know, to try to get a product down. So, and investors are not going to keep putting money in, they get tired, and all the employees and founders get diluted if you keep going for a long time. So I think there you have to have made enough, not only want to have impact, but you've made progress, like let's say you have some good animal data. And I usually think that if something we're going to do, we probably have a paper ideally in a top journal like Science, Nature, Cell, and also you want really good patents, you know, that cover what you did. And for me, I haven't always done it for just those reasons, and a lot of times some of the students, postdocs in the lab, they've worked on this for five, six years, and they want to see it make a difference in the world, so they want to see that happen. So it would have those elements.
Susan Hockfield 12:13 ↗
Yeah, that's terrific. So if I think for our young colleagues, have this question for you, which is, I'm sure that through your career there have been many who didn't believe in your thesis or your work. And what did you do? Do you do, maybe there's never any doubt anymore about what Bob Langer can do, but what did you do to start to kind of keep going and persevere toward your goals when, you know, there are just a lot of doubters out there?
Robert Langer 12:41 ↗
Yeah, well, a couple of things I think that helped me. I mean, one was when I mentioned Folkman, who was my doctor boss, you know, he had that, a lot of people really criticized the fact that newspapers, you know, Wall Street Journal, New York Times, other places, you know, they said this, even Science magazine, they wrote, I think 1976 or '7, there was a big article about blood vessel growth, and it was a figment of his imagination. And yet he kept persevering, and I think, you know, watching as a role model, that was great, you know, very helpful to me. And I think that was one thing. Second thing really is I was very lucky when I was a professor here. I had two very close friends, still, Alex van Oosbree, who was, and Mike, and, you know, we'd get together very frequently and sort of trade stories, and I think they were very helpful in supporting me, and I hope I them. Thank you.
Susan Hockfield 13:51 ↗
And one last thing, again, I'm thinking about where I was when I was, you know, still a graduate student, a postdoc, and, you know, the things that I didn't know that I kind of wish I had not known. But so in retrospect, when you think about your student trainee experiences, what prepared you for company founding? This is something we don't have classes in, right?
Robert Langer 14:14 ↗
Yeah. So, so let me try to answer that in a couple of ways. First, nothing did, you know, but I think a couple of things helped. One, when I helped start this school for low-income kids, you know, I got, I was developing math science curriculum, which had to raise money. I mean, they, you know, try to raise money for NIH, man, that's hard. Trying to raise money for this was super hard because they were, you know, they were poor, you know, had money, and people weren't going to give that. So I had a, you know, so I started working on grants and, you know, trying to help find money where he could. So that was one thing that was helpful. The second thing that was helpful, though, was actually Dr. Folkman's view of believing anything was possible. And neither of those were about starting the company, but they, those are elements that I think are very important, you know, to doing it, you know, not giving up, keep trying, keep trying, and believing anything is possible. You know, one thing, though, that might, you know, if I go to tips about all the mistakes I made, you know, that the very first time we started a company, this was now probably over 40 years ago. You know, at Alza, believe it or not, I forgot to mention my face. We should start a company. And part one of the reasons we did it is we couldn't get, I couldn't get big companies to like really develop the things that I was doing. And that meant a lot to me. I really wanted to consciously write bigs. Susan was saying, I wanted to see things make a difference, and I thought it could. And yet I got these two large companies actually licensed stuff from us and started doing it. And after a year or two, they just gave up. So Alex said to me, well, we should start our own company. But just to maybe not tip so much, but just to illustrate about why I don't think it's anything you can really learn. You have to learn by your failures or by doing. So the first Alex said, you know, you have to find a CEO. We were going to stay at MIT. So one day he said, oh, I was just at this company. It's a multi-billion dollar company. There's this guy who's a senior director, and he's telling me, he said he's willing to leave this company to be our CEO. And I said, geez, that's great. You know, so we hired him to be CEO. Turns out he was getting fired. But it just shows you. So the other thing, which is, which I also learned, it took me a number of years to learn this, you know. So people say, you know, when you get venture capital, that people, you know, they give quite a bit of money, and everybody says, but they, you know, you have to be careful because you should have lawyers come over this, the contracts and everything go. So we did. Lawyers said everything was fine. But then one of the exits that happens for companies could be, could be a good thing, is the company got bought about four or five years later by another company. And it turns out that when the thing was signed, there's venture capital issued money, but they have a thing that's called participating preferred shares. You know, it's perfectly legal. But what it means is that if the company got acquired in a certain way, not only would the investors get what they put in, you know, let's say they own, I'll make this up, 80% of the company, but then they get an additional 80% of what's left, you know, that's so that would mean that there'd be 4% left for everybody else in that example. And I mean, it's perfectly legal, but I've never agreed to that after that, you know. I mean, but you know, you just, you just kind of learn by mistakes. And by the way, they're perfect. That's perfectly, both of those were perfectly, you know, legal things, but you only learn by, I think, your mistakes.
Susan Hockfield 18:11 ↗
So we're going to turn to you. That, that, I mean, I could talk to both, we can talk for hours. But now it's time for your questions because we really want this to help you figure out, you know, get answers to questions that you have. There are mics on the side, and if you'd use them, that would be really helpful because the auditorium by itself doesn't have great, you know, acoustics. So please come to the mics, and Bob will do his best to answer your questions.
Audience Member 18:43 ↗
And you had there as well. Oh, so like, how did that interaction work, and how, how can you, what can the school do to push more people to be this successful, but at the same time, what can, what would you have wished MIT to do more, or what makes MIT special and allowed you to do what you did?
Robert Langer 19:07 ↗
Do you want me to go for, so I can have both? But, but so at any rate, I, for me, I mean, really what's special about MIT, there's several things that are special about MIT, but one of them is, I mean, the biggest one to me has been your students, your postdocs, and your colleagues. So I think that that has been, you know, when I look back over the last 50 years for me, having had such amazing students and colleagues to collaborate with, I mentioned a couple, but I could mention more. So I think MIT gives you that. And if they gave you nothing else, that, that, that would probably be pretty good. But there are other things MIT actually, and from a company standpoint, since we're talking about, has actually quite a few things that are helpful. I know even when I get started, they have this industrial liaison program and broad companies, and we have a technology licensing office that's very professional. In fact, when I talk with my colleagues and I collaborate with people at, you know, different hospitals, and they always say, well, let's make sure we send the patent throughout MIT, you know, and, and so we probably typically do, and, and there's, you know, all kinds of other things. Now, there's the center, which provides grants, and I could go on and on. I mean, there's a lot of just different features and...
And I would just add, I still, you know, that if I look at the administration, that one of the things, probably kind of, but I'm not insult other schools, but, but yeah, well, that's okay. But, but, but, you know, one of the things, like I remember I was in one meeting and they, what they, this place was saying, you know, they, they put all of a lot of different schools up about how they were doing entrepreneurs, and they said that their school was, there were three schools that were at the top: MIT, Stanford, and this school. And then they, and I thinking I had so many people I knew at that schools kept complaining about that they weren't doing that good a job, and, and so I brought that up, and but they kept saying, well, we have all these statistics, we have all these statistics. Anyhow, so, but at the next meeting, actually the president of that university said, you know, we have all these statistics, but the difference is MIT celebrates this. They celebrate entrepreneurism, they celebrate, you know, innovation, and, and we don't, you know, and I think you are a great example of that. I mean, in so many ways, so, and, and others too. So I think that that is, you know, a lot of places, I mean, just to go over it because people may not necessarily realize this, even apologize for it. I think there's, and, and it's not, and it can be apologized for, is sometimes people are so worried about conflict of interest. The newspapers write stories that are, you know, this is bad, that's bad, but MIT consistently is celebrating innovation and the people who do it. I mean, what I mean, here's a great example of, of this, you know, this, this thing that you've, you know, all brought up for Heels. So anyhow, so that, that's just, I guess, part of how I'd answer it.
Susan Hockfield 22:44 ↗
Thank you. I think so.
Audience Member 22:52 ↗
Hi, I'm sad. I do. You can tell this like in my eye, but I'm just curious. I'm a junior scientist and I've done a lot of experiments. It's kind of been difficult to kind of find to...
Susan Hockfield 23:12 ↗
This better. Perfect.
Audience Member 23:14 ↗
Okay. Right. So I'm a junior scientist. I do a lot of experiments, and one thing I found is that a lot of times I kind of hit a dead end or have a lot of ideas and I don't go from there. I'm curious, you know, based on your career, have you found that, you know, there are times where you have to kind of play your drum that kind of exhausted every option? I'm sorry.
Susan Hockfield 23:31 ↗
Why difficult? Maybe it's the microphone. I don't know. I think you need to keep your really close to the mic.
Audience Member 23:41 ↗
I guess. Okay. I was on a very quiet voice.
Susan Hockfield 23:44 ↗
You know, what other possibility if you just maybe come closer and then I'll, I'll repeat the question as I understand it.
Robert Langer 24:06 ↗
Yeah. Well, okay. So his question is, when, when do you know to stop the idea? You know, I, I think it's a, that's a very good question for which there's not an easy answer to me. You know, and I think it's a little bit different academically than in industry, but, you know, I, I think academically if you're trying to discover something, you know, you, you might end up doing it for many years if you feel it's important and you maybe make a little bit of progress here and there, but if it's really important, I guess I keep doing it academically. Industrially though, that's different. You know, I think you try to think of killer experiments that can tell you, will, will it, will it work? And, and that's actually gets it to experimental design. Is there an experiment maybe again a medicine on an animal like we often have thought that, uh, you doing things on non-human primates? If you can get to that point, you know, that, that, and let's say you see really bad toxicity, you know, that, that might tell you to stop. And again, sometimes things get in humans too, and, and, and you get, you know, really bad toxicity or something. So things like that, you have to think if, if you did that, whether there's some simple way to get around it. So I, I don't know if I give up right away, but, but I, but it would make me think about it real hard if, if, if I started to, you know, see something that wasn't working in, in an animal model and in humans. By the way, if I saw it not working in or causing safety problems in a mouse, I'd be concerned too. But a lot of times something will work in a mouse or be safe in a mouse and it won't be safe in a primate. That, that's just one way of thinking.
Susan Hockfield 25:49 ↗
Great. Over here.
Audience Member 25:52 ↗
Hello. I'm a post.
Susan Hockfield 25:54 ↗
Again, you have to get your close to the mic. Yeah, that would be better. That's easier.
Audience Member 25:59 ↗
Hi, I'm a post at the Koch Institute. I work with Christopher Nabel. And...
Yeah, the question that I want to ask is, so obviously as a... but also as an inventor, and I'm assuming also to some degree as an investor at this point, you come across many, many projects, many propositions to study something. It can be from your undergrad, from your students, or it can be from someone that has a project. So I'm very curious to know what makes you say yes versus what makes you say no to go after that specific project. And if that is too generic or too general, maybe what is something that you couldn't say no to, for instance, because it touches you personally or because it's something that you really feel very strong about.
Robert Langer 26:56 ↗
Yeah. Well, so to me, I guess the answer is if I think something has a lot of impact, that makes me highly likely to say yes. I mean, an example which we've been very active in, and it has actually led to some companies even though that wasn't necessarily the intent, was, you know, Bill Gates came to see me about 14 years ago with the point like, well, our work certainly affected, you know, millions, maybe billions of people, but could we do things to help the developing world? And by the way, I wasn't thinking that when I was 77 years old I'd have this, you know, really big lab, lots of people. But that to me was very compelling, that we could make a difference in so many lives. And through that work we've been in 25 clinical trials, and it has led to a number of companies, and that whole foundation's been very, very helpful to a lot of the things that we've done. So that would be an answer, you know, all of this, I suppose, about impact or perceived impact.
Audience Member 28:08 ↗
Thank you.
Susan Hockfield 28:16 ↗
Use the mic.
Robert Langer 28:18 ↗
Yeah, we got a better microphone.
Audience Member 28:21 ↗
Is it audible?
Susan Hockfield 28:23 ↗
Yes.

33 more exchanges in this transcript

Sign in free to read the rest of this interview. No card required.

Sign in to read the full transcript

Cite this transcript

APA, MLA, BibTeX
APA

Langer, R. (2026, May 6). Bob Langer MIT HEALS Fireside Chat 2026 05 06 Broad Institute [Interview transcript]. Jack Kwan. CEOInterviews.AI. https://ceointerviews.ai/interview/3094512/

MLA

Robert Langer. "Bob Langer MIT HEALS Fireside Chat 2026 05 06 Broad Institute." Jack Kwan, 6 May. 2026. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/3094512/.

BibTeX
@misc{langer2026_3094512,
  author       = {Robert Langer},
  title        = {Bob Langer MIT HEALS Fireside Chat 2026 05 06 Broad Institute},
  howpublished = {Interview transcript, Jack Kwan. CEOInterviews.AI},
  year         = {2026},
  month        = {may},
  url          = {https://ceointerviews.ai/interview/3094512/},
  note         = {Speaker-attributed transcript with timestamps}
}